ATE162402T1 - Oraler an der oberfläche von erythrozyten gebundene antigene beinhaltender impfstoff - Google Patents

Oraler an der oberfläche von erythrozyten gebundene antigene beinhaltender impfstoff

Info

Publication number
ATE162402T1
ATE162402T1 AT91908727T AT91908727T ATE162402T1 AT E162402 T1 ATE162402 T1 AT E162402T1 AT 91908727 T AT91908727 T AT 91908727T AT 91908727 T AT91908727 T AT 91908727T AT E162402 T1 ATE162402 T1 AT E162402T1
Authority
AT
Austria
Prior art keywords
pct
erythrocytes
vaccine containing
oral vaccine
containing antigens
Prior art date
Application number
AT91908727T
Other languages
English (en)
Inventor
Gerald Toh Pang
Robert Llewellyn Clancy
Original Assignee
Flustat Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flustat Pty Ltd filed Critical Flustat Pty Ltd
Application granted granted Critical
Publication of ATE162402T1 publication Critical patent/ATE162402T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT91908727T 1990-04-24 1991-04-24 Oraler an der oberfläche von erythrozyten gebundene antigene beinhaltender impfstoff ATE162402T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPJ978390 1990-04-24

Publications (1)

Publication Number Publication Date
ATE162402T1 true ATE162402T1 (de) 1998-02-15

Family

ID=3774614

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91908727T ATE162402T1 (de) 1990-04-24 1991-04-24 Oraler an der oberfläche von erythrozyten gebundene antigene beinhaltender impfstoff

Country Status (14)

Country Link
US (1) US5643577A (de)
EP (1) EP0528859B1 (de)
JP (1) JPH05506233A (de)
KR (1) KR100186783B1 (de)
AT (1) ATE162402T1 (de)
AU (1) AU646257B2 (de)
BR (1) BR9106374A (de)
CA (1) CA2080477A1 (de)
DE (1) DE69128782T2 (de)
DK (1) DK0528859T3 (de)
ES (1) ES2113882T3 (de)
GR (1) GR3026569T3 (de)
SG (1) SG46225A1 (de)
WO (1) WO1991016073A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882649A (en) * 1990-04-24 1999-03-16 Flustat Pty. Ltd. Oral vaccine comprising antigen surface-associated with red blood cells
GB2294268A (en) 1994-07-07 1996-04-24 Procter & Gamble Bleaching composition for dishwasher use
GB9517269D0 (en) * 1995-08-23 1995-10-25 Cortecs Ltd Vaccines
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US5993852A (en) * 1997-08-29 1999-11-30 Pharmaderm Laboratories Ltd. Biphasic lipid vesicle composition for transdermal administration of an immunogen
WO1999026508A1 (en) 1997-11-21 1999-06-03 The Procter & Gamble Company Product applicator
GB2369094A (en) 2000-11-17 2002-05-22 Procter & Gamble Packaging assembly for sheets of water-soluble sachets
WO2002060416A1 (en) * 2001-02-01 2002-08-08 Gendel Limited Polypeptide delivery system and method for their preparation
US20060083702A1 (en) * 2004-04-02 2006-04-20 Thomas Fondin Hair fiber treating method
US7666354B2 (en) 2004-12-22 2010-02-23 Fujifilm Corporation Composition for sterilization comprising ω-alkoxyperoxycarboxylic acid
WO2007150020A1 (en) * 2006-06-23 2007-12-27 Simon Paul M Targeted immune conjugates
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
DK2318832T3 (da) 2008-07-15 2014-01-20 Academia Sinica Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
GB0901207D0 (en) 2009-01-26 2009-03-11 Innospec Ltd Chelating agents and methods relating thereto
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
WO2011138032A2 (en) 2010-05-05 2011-11-10 Artemev, Timur Universal influenza vaccines and methods for their generation
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
WO2012059112A1 (en) * 2010-11-01 2012-05-10 Mahmoud Abdel Wahed Rafea Development of medical products based on a new discovered function of red blood cells
CN107115314B (zh) * 2011-06-02 2022-04-29 加利福尼亚大学董事会 膜包封的纳米颗粒及使用方法
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
WO2013059343A1 (en) 2011-10-17 2013-04-25 Massachusetts Institute Of Technology Intracellular delivery
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
EP2958586B1 (de) 2013-02-21 2018-09-05 Boehringer Ingelheim Vetmedica GmbH H5-proteine aus dem h5n1-influenzavirus zur verwendung als arzneimittel
WO2014210397A1 (en) 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
EP3013347B1 (de) 2013-06-27 2019-12-11 Academia Sinica Glykankonjugate und verwendung davon
US10124336B2 (en) 2013-08-16 2018-11-13 Massachusetts Institute Of Technology Selective delivery of material to cells
EP3041484B1 (de) 2013-09-06 2021-03-03 Academia Sinica Humane inkt-zell-aktivierung mittels glykolipiden mit veränderten glycosylgruppen
KR20160104727A (ko) 2014-01-16 2016-09-05 아카데미아 시니카 암의 치료 및 검출을 위한 조성물 및 방법
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
TWI797430B (zh) 2014-03-27 2023-04-01 中央研究院 反應性標記化合物及其用途
KR20170010003A (ko) 2014-05-27 2017-01-25 아카데미아 시니카 박테로이드 기원의 푸코시다제 및 이의 사용 방법
JP2017518989A (ja) 2014-05-27 2017-07-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 抗ｃｄ２０糖操作抗体群およびその使用
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
EP4116329A1 (de) 2014-05-27 2023-01-11 Academia Sinica Anti-her2-glykoantikörper und verwendungen davon
JP7063538B2 (ja) 2014-05-28 2022-05-09 アカデミア シニカ 抗ＴＮＦα糖操作抗体群およびその使用
EP3191500A4 (de) 2014-09-08 2018-04-11 Academia Sinica Aktivierung menschlicher inkt-zellen mithilfe von glykolipiden
CN122564053A (zh) 2014-10-31 2026-08-14 麻省理工学院 递送生物分子至免疫细胞
WO2016077761A1 (en) 2014-11-14 2016-05-19 Massachusetts Institute Of Technology Disruption and field enabled delivery of compounds and compositions into cells
AU2016206870B2 (en) 2015-01-12 2022-02-17 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
AU2015378564A1 (en) 2015-01-24 2017-07-13 Academia Sinica Novel glycan conjugates and methods of use thereof
JP6925984B2 (ja) 2015-07-09 2021-08-25 マサチューセッツ インスティテュート オブ テクノロジー 無核細胞への物質の送達
US11613759B2 (en) 2015-09-04 2023-03-28 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
CN109195996A (zh) 2016-03-08 2019-01-11 中央研究院 N-聚醣及其阵列的模组化合成方法
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
KR20250126039A (ko) 2022-12-16 2025-08-22 이노스펙 리미티드 미립자 조성물
GB202409569D0 (en) 2024-07-02 2024-08-14 Innospec Performance Chemicals Italia Srl Compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136167A (en) * 1975-06-12 1979-01-23 Internationale Octrooi Maatschappij "Octropa" B.V. Process for reducing the incidence of neonatal diarrhoea in pigs
DE2551208C3 (de) * 1975-11-14 1981-05-27 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung einer stabilen Erythrozyten-Präparation
FR2355507A1 (fr) * 1976-06-25 1978-01-20 Inst Nat Sante Rech Med Vaccin antiparasitaire par voie orale, son procede de preparation et sa methode d'application chez les mammiferes
SU649435A1 (ru) * 1977-06-24 1979-02-28 Уфимский Научно-Исследовательский Институт Вакции И Сывороток Им. И.И.Мечникова Способ приготовлени эритроцитов
US4403037A (en) * 1980-10-10 1983-09-06 American Hoechst Corporation Erythrocyte preparations and use thereof in hemagglutination tests
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4904468A (en) * 1987-06-08 1990-02-27 Norden Laboratories, Inc. Canine coronavirus vaccine

Also Published As

Publication number Publication date
AU646257B2 (en) 1994-02-17
WO1991016073A1 (en) 1991-10-31
JPH05506233A (ja) 1993-09-16
KR100186783B1 (ko) 1999-05-01
EP0528859A1 (de) 1993-03-03
ES2113882T3 (es) 1998-05-16
US5643577A (en) 1997-07-01
HK1004060A1 (en) 1998-11-13
CA2080477A1 (en) 1991-10-25
DE69128782T2 (de) 1998-09-10
DE69128782D1 (de) 1998-02-26
EP0528859B1 (de) 1998-01-21
EP0528859A4 (en) 1993-08-04
GR3026569T3 (en) 1998-07-31
SG46225A1 (en) 1998-02-20
AU7753191A (en) 1991-11-11
BR9106374A (pt) 1993-03-30
DK0528859T3 (da) 1998-09-14

Similar Documents

Publication Publication Date Title
DE69128782D1 (de) Oraler an der oberfläche von erythrozyten gebundene antigene beinhaltender impfstoff
DE69534992D1 (de) Mutierendes enterotoxin als nichttoxisches orales adjuvans
DK257485A (da) Farmaceutiske praeparater til oral indgift
ES2176232T3 (es) Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.
AR063315A2 (es) Composicion que comprende un virus, y metodos para concentrar y purificar preparados de virus
ES2118963T3 (es) Vacunas combinadas, que contienen antigeno de superficie de la hepatitis b y otros antigenos.
EA199800272A1 (ru) Фактор, стимулирующий дендритные клетки
AU2684792A (en) Porcine reproductive respiratory syndrome vaccine and diagnostic
DE69943170D1 (de) Immunologische Zusammensetzung und Impfstoffe, die einen auf N-Formyl-Methionyl Peptide bestehenden Adjuvans enthalten
CA2098021A1 (en) Composition Used as a Therapeutic Agent Against Chronic Viral Hepatic Diseases
KR850001700A (ko) 단순 헤르페스 바이러스 서브유니트 왁진(Herpes Simplex Virus Subuait Vaccine)의 제조방법
CA2115927A1 (en) Peptides for inducing cytotoxic t-lymphocyte responses to hepatitis b virus
DK0666754T3 (da) Syntetisk lungesurfactant med antioxidant-egenskaber
Rhodes Modulation of macrophage Fc receptor expression in vitro by insulin and cyclic nucleotides
CA2078605A1 (en) Chicken anaemia agent vaccine
DK482185A (da) Peptider, deres fremstilling og anvendelse som laegemidler
HK141494A (en) Peptide fragments of HIV
FI885441L (fi) Nya vaccin.
DK178188D0 (da) Antivirusmiddel
DE3886371D1 (de) Herstellung des hblv-virus in der hsb-2 zell-linie.
IT1177147B (it) Composizione farmaceutica per combattere infezioni virali, e procedimento di uso per le infezioni virali
EP0090660A3 (de) Neisseria Gonorrhöe Vakzin
ATE18007T1 (de) Hepatitisimpfstoff.
ES2062502T3 (es) Una proteina de factor i pura y un procedimiento para obtener dicha proteina.
ATE234861T1 (de) Influenzaimpfstoff, der als sinergistischer zusatzmittel influenzavirusinnenkörper enthält

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee